Cabotegravir-rilpivirine long-acting injectable regimen: an analysis of the causes of interruption and impact of genotypic drug resistance in a multicentric cohort

被引：0
|
作者：
Canavesi, Giada [1 ]
Mena, Maurizio [1 ]
Zaninetta, Elena [2 ,3 ]
Gazzola, Lidia [2 ,3 ]
Bini, Teresa [2 ,3 ]
Orofino, Giancarlo [4 ,5 ]
De Vito, Andrea [6 ,7 ]
Madeddu, Giordano [6 ,7 ]
Grillo, Chiara [8 ,9 ]
Bartalucci, Claudia [10 ,11 ]
Centorrino, Federica [10 ,11 ]
Squillace, Nicola [12 ,13 ]
Bonfanti, Paolo [12 ,13 ]
Tiecco, Giorgio [14 ,15 ]
Foca, Emanuele [14 ,15 ]
Menozzi, Marianna [16 ,17 ]
Guaraldi, Giovanni [16 ,17 ]
Bana, Nicolas Brian [18 ]
Cavazza, Giovanni [18 ]
Rossotti, Roberto [18 ]
Lo Caputo, Sergio [8 ,9 ]
Di Biagio, Antonio [10 ,11 ]
Rusconi, Stefano [1 ]
机构：
[1] Osped Nuovo Legnano, Infect Dis Unit, ASST Ovest Milanese, Legnano, Italy
[2] San Paolo Hosp, Infect Dis Unit, ASST Santi Paolo & Carlo, Milan, Italy
[3] Dipartimento Sci Salute, Milan, Italy
[4] Amedeo Savoia Hosp, Infect Dis Unit, Turin, Italy
[5] Univ Turin, Turin, Italy
[6] Azienda Osped Univ Sassari, Infect Dis Unit, Sassari, Italy
[7] Univ Sassari, Sassari, Italy
[8] Azienda Osped Univ Osped Riuniti Foggia, Infect Dis Unit, Foggia, Italy
[9] Univ Foggia, Foggia, Italy
[10] Osped Policlin San Martino, Infect Dis Unit, Genoa, Italy
[11] Univ Genoa, Genoa, Italy
[12] IRCCS San Gerardo Tintori, Infect Dis Unit, Monza, Italy
[13] Univ Milano Bicocca, Monza, Italy
[14] Spedali Civili Brescia, Infect Dis Unit, Brescia, Italy
[15] Univ Brescia, Brescia, Italy
[16] Azienda Osped Univ Modena, Infect Dis Unit, Modena, Italy
[17] Univ Modena & Reggio Emilia, Modena, Italy
[18] ASST Grande Osped Metropolitano Niguarda, Infect Dis Unit, Milan, Italy
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2024年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
P074
引用
收藏
页码：86 / 88
页数：3
相关论文
共 50 条
  • [31] Is Nonsustained Viral Suppression With Long-Acting Cabotegravir and Rilpivirine Really Independent of Drug Levels?
    Thoueille, Paul
    Marzolini, Catia
    Guidi, Monia
    Cavassini, Matthias
    Decosterd, Laurent A.
    CLINICAL INFECTIOUS DISEASES, 2025,
  • [32] Effectiveness and timing of viral load measurement in real-world use of long-acting cabotegravir-rilpivirine in people with HIV
    Fernandez-Hinojal, F.
    de Gea Grela, A.
    Martin-Carbonero, L.
    Valencia, E.
    Mican, R.
    Busca, C.
    Ramos, L.
    Arribas, J. R.
    Gonzalez-Garcia, J.
    Bernardino, J. I.
    Montes, M. L.
    HIV MEDICINE, 2023, 24 : 119 - 120
  • [33] Rilpivirine and cabotegravir trough concentrations in people with HIV on long-term treatment with long-acting injectable antiretrovirals
    Cossu, Maria Vittoria
    Cattaneo, Dario
    Moschese, Davide
    Giacomelli, Andrea
    Soloperto, Sara
    D'Avolio, Antonio
    Antinori, Spinello
    Gori, Andrea
    Rizzardini, Giuliano
    Gervasoni, Cristina
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2024, 79 (05) : 1126 - 1132
  • [34] Off-label use of long-acting injectable cabotegravir/rilpivirine in viremic patient living with HIV
    Jorgensen, N. M.
    Larsen, L.
    HIV MEDICINE, 2023, 24 : 711 - 711
  • [35] Therapeutic review of cabotegravir/rilpivirine long-acting antiretroviral injectable and implementation considerations at an HIV specialty clinic
    Howe, Zach W.
    Norman, Sarah
    Lueken, Abbie F.
    Huesgen, Emily
    Farmer, Eric K.
    Jarrell, Kaitlyn
    Mathis, Joscelyn E.
    Bonham, Kyle W.
    Hahn, Julie
    PHARMACOTHERAPY, 2021, 41 (08): : 686 - 699
  • [36] Early Experience and Effectiveness of Long-Acting Injectable Cabotegravir and Rilpivirine in a South Side Chicago HIV Clinic
    Liegeon, Geoffroy
    Kaperak, Christopher
    Friedman, Eleanor E.
    Djuricich, Paul
    Dawdani, Alicia
    Stafford, Kane
    Plotkin, Sophie
    Schmitt, Jessica
    Hazra, Aniruddha
    Christopoulos, Katerina A.
    Schneider, John A.
    Mcnulty, Moira C.
    OPEN FORUM INFECTIOUS DISEASES, 2025, 12 (03):
  • [37] Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential
    Fernandez, Cristina
    van Halsema, Clare L.
    HIV AIDS-RESEARCH AND PALLIATIVE CARE, 2019, 11 : 179 - 192
  • [38] Uptake and discontinuation of the long-acting duo in the Swiss HIV Cohort Study: Preliminary analysis on cabotegravir plus rilpivirine
    Ramirez, J. J. Duran
    Kusejko, K.
    Metzner, K. J.
    Huber, M.
    Martin, Y.
    Stockle, M.
    Calmy, A.
    Decosterd, L. A.
    Cavassini, M.
    Bernasconi, E.
    Schmid, P.
    Gunthard, H. F.
    Braun, D. L.
    HIV MEDICINE, 2023, 24 : 79 - 81
  • [39] Drug Resistance Mutations (DRMs) for Long-Acting Injectable Cabotegravir and Rilpivirine (CAB/RPV LAI) in the HIV-1 Subtype A6 Epidemic in Poland
    Zaleski, Andrzej
    Lembas, Agnieszka
    Dyda, Tomasz
    Osinska, Joanna
    Jablonska, Joanna
    Stempkowska-Rejek, Justyna
    Orzechowska, Justyna
    Wiercinska-Drapalo, Alicja
    MICROORGANISMS, 2025, 13 (02)
  • [40] Effectiveness of injectable long-acting cabotegravir and rilpivirine for the treatment of HIV-1: Results from the Dutch ATHENA national observational cohort
    Jongen, V.
    Wit, F.
    van Eeden, A.
    Brouwer, A.
    Soetekouw, R.
    El Moussaoui, R.
    Stalenhoef, J.
    Sigaloff, K.
    Mudrikova, T.
    Gisolf, J.
    Wensing, A.
    van der Valk, M.
    HIV MEDICINE, 2023, 24 : 167 - 169
12345